Decision: Favourable

Study Title:

PIONEER IV trial: Non-inferiority of angiography-derived physiology guidance versus usual care in an All-comers PCI population treated with unrestricted use of the Healing-Targeted Supreme (HT SupremeTM) drug- eluting stent and P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy: the PIONEER IV trial

  • NREC Code:

    21-NREC-MD-003

  • Decision:

    Favourable

  • Meeting Date:

    24/06/2021

  • Study Type:

    MD application

  • Principal Investigator:

    Prof Patrick Serruys

  • PI Institution:

    NUIG

  • Sponsor:

    NUIG

Scroll to Top